Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27921111 | 0.78 | GABRA1 (0.42) | GABRA1GABRB2MEN1ALDH1A1ALOX15 | |
| SCHEMBL16098867 | 0.75 | PDE7A (0.40) | PTGDRPTGDR2GABRA1GABRB2ALDH1A1 | |
| SCHEMBL17924772 | 0.74 | GABRA1 (0.40) | GABRA1GABRB2MEN1ALDH1A1ALOX15 | |
| SCHEMBL10410817 | 0.73 | ALDH1A1 (0.33) | GABRA1GABRB2MEN1ALDH1A1ALOX15 | |
| SCHEMBL671144 | 0.73 | PTGDR (0.40) | PTGDRPTGDR2GABRA1GABRB2MEN1 | |
| SCHEMBL28193331 | 0.72 | AURKA (0.38) | GABRA1GABRB2MEN1ALDH1A1ALOX15 | |
| SCHEMBL21546530 | 0.72 | PTGDR (0.47) | PTGDRPTGDR2GABRA1GABRB2MEN1 | |
| SCHEMBL7042258 | 0.71 | CYP3A4 (0.44) | PTGDRPTGDR2GABRA1GABRB2ALDH1A1 | |
| SCHEMBL7037293 | 0.71 | GABRA1 (0.38) | GABRA1GABRB2MEN1KMT2AMAP4K4 | |
| SCHEMBL7556444 | 0.71 | GABRA1 (0.48) | GABRA1GABRB2MEN1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708340-B2 | Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2014146994-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146994-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185795-A1 | UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS | FABP1, FABP5, FABP2 | PTGDR 2553/4885PTGDR2 2753/4885GABRA1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.